HIGHLIGHTS
- who: Omar Faruq and colleagues from the Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M S , Canada have published the Article: Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma, in the Journal: (JOURNAL)
- what: The authors show that MDM2 is associated with poor prognosis. The authors demonstrate that MDM2 is a potential prognostic biomarker and therapeutic target in MM. The authors characterize MX69 as a potential anti-myeloma agent with cytotoxic effects in MM cells irrespective of p53 status, both alone and in combination with current frontline . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.